1. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer

2. Program Goals

3. Distribution of Breast Cancer Subtypes at Diagnosis by Age

4. Hormonal Therapy for Advanced Breast Cancer: Milestones

5. Diagnosis and Treatment of HR+ mBC

6. Cyclin-Dependent Kinases and Cell Cycle Progression

7. CDK 4/6 Inhibition Is Most Effective in ER+/Luminal Breast Cancer Cells

8. Efficacy of First-Line Endocrine Therapy

9. PALOMA-3: Palbociclib and Fulvestrant, Phase 3 (Interim Study Analysis, N = 521)

10. Ongoing Studies With CDK 4/6 Inhibitors

11. PALOMA-1: Design

12. PALOMA-1/TRIO-18: Progression-free Survival

13. Palbociclib

14. Combination of Palbociclib + Letrozole: Dosing and Administration

15. Most Common Treatment-Related AEs ≥ 10%

16. CDK 4/6 Inhibition: Adverse Effects

17. Abbreviations

18. Abbreviations (cont)

19. Abbreviations (cont)

20. Abbreviations (cont)

21. References

22. References

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)